有或没有慢性肾病的猫的血液成纤维细胞生长因子23浓度：范围综述

摘要来源：

一校：刘玲

二校：kenda

编辑：百可事乐

摘要

本研究通过对健康无氮质血症的猫和患有慢性肾病（CKD）的猫的血液成纤维细胞生长因子23（FGF-23）浓度研究进行了范围综述，旨在描述现有文献的数量和性质，确定已发表的研究是否提供了充分的证据支持在临床实践中使用FGF-23作为生物标志物，并找出现有知识的空白。

参照范围综述报告规范（PRISMA Extension for Scoping Reviews，PRISMA-ScR）指南设计和撰写这篇范围综述。利用在线数据库，筛选出截至2022年12月发表的关于健康猫和慢性肾病猫血液中FGF-23浓度的观察性和临床研究。选取了关于 FGF-23 浓度的研究和猫群特征以及描述性数据。

共审查了205篇文献，其中17篇被保留纳入研究。大多数研究是回顾性的。大部分研究包括患有国际肾病兴趣协会（International Renal Interest Society，IRIS）2-4期CKD的猫，存在一些差异。文献中探讨的要点包括：①CKD不同阶段的FGF-23浓度，②饮食磷限制对FGF-23浓度的影响，③FGF-23浓度与血磷、钙和镁浓度的关系，④进行性 CKD 患猫的FGF-23浓度。与健康猫相比，CKD患猫的FGF-23浓度往往较高，但健康猫与CKD患猫之间存在重叠，并且在CKD的不同阶段存在明显差异。

FGF-23是管理和监测猫磷酸盐过量的重要生物标志物。研究支持，FGF-23 浓度的测量在临床实践中具有多个潜在应用，但证据有限。研究CKD患猫的FGF-23，需要进行纵向、前瞻性的研究，根据当前指南标准化CKD诊断并按CKD分期将猫分类。这些研究应包括早期、无氮质血症的CKD猫，并使用可在市场上买到的试剂盒，以便在不同研究中的结果进行比较。

原文：

Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review

Abstract

Objectives

This study undertook a scoping review of research on blood fibroblast growth factor 23 (FGF-23) concentrations in healthy non-azotemic cats and cats with chronic kidney disease (CKD) to describe the volume and nature of existing literature, to determine whether published studies provide adequate evidence to support the use of FGF-23 as a biomarker in clinical practice and to identify any existing gaps in knowledge.

Methods

PRISMA Extension for Scoping Reviews guidelines were used to design and perform the scoping review. Online databases were used to identify observational and clinical studies of blood FGF-23 concentrations in healthy cats and cats with CKD published before December 2022. Study and population characteristics and descriptive data on FGF-23 concentrations were extracted.

Results

A total of 205 publications were reviewed; 17 were retained for inclusion. Most studies were retrospective. Most studies included cats with International Renal Interest Society stage 2–4 CKD, with some variation. Key concepts explored in the literature include FGF-23 concentrations by CKD stage, effect of dietary phosphate restriction on FGF-23 concentrations, relationship between FGF-23 concentrations and blood phosphorus, calcium and magnesium concentrations, and FGF-23 concentrations in cats with progressive CKD. FGF-23 concentrations tended to be higher in cats with CKD compared with healthy cats, with an overlap between healthy and CKD populations, and there was significant variation within stages of CKD.

Conclusions and relevance

FGF-23 is a biomarker of interest for the management and monitoring of phosphate overload in cats. Studies support several potential clinical applications for measuring FGF-23 concentration in practice; however, evidence is limited. Research on FGF-23 in cats with CKD would benefit from longitudinal, prospective studies that standardize CKD diagnosis and categorize cats by stage using current guidelines. Studies should include cats with early-stage, non-azotemic CKD and use commercially available assays so such results are comparable across studies.